SteelPeak Wealth Boosts Stake in Johnson & Johnson

Investment firm increases holdings in pharmaceutical giant

Apr. 7, 2026 at 9:28am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up of the intricate gears, mechanisms, and components of a medical device, captured in a heavy, industrial style that conveys the sophistication and precision of Johnson & Johnson's manufacturing processes.An extreme close-up of the inner workings of a Johnson & Johnson medical device, highlighting the company's technological expertise and manufacturing capabilities.New Brunswick Today

SteelPeak Wealth LLC, a financial advisory firm, has increased its position in Johnson & Johnson (NYSE: JNJ) by 8.8% in the fourth quarter, according to a recent SEC filing. The firm now owns 84,071 shares of the healthcare company's stock, valued at $17.4 million.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Institutional investors closely monitor changes in ownership of major blue-chip stocks like JNJ, as it can signal broader market trends and investor sentiment.

The details

According to the 13F filing, SteelPeak Wealth added 6,810 shares of Johnson & Johnson during the fourth quarter of 2025. This brings the firm's total holdings in JNJ to 84,071 shares. The increased stake represents 8.8% growth in SteelPeak's position in the company.

  • SteelPeak Wealth LLC filed the 13F report for the fourth quarter of 2025.

The players

SteelPeak Wealth LLC

A financial advisory firm that manages investments and provides wealth management services.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer packaged goods.

Got photos? Submit your photos here. ›

The takeaway

The increase in SteelPeak Wealth's stake in Johnson & Johnson reflects the firm's confidence in the healthcare giant's long-term growth prospects. As a diversified leader in the pharmaceutical and medical device industries, JNJ remains an attractive investment for institutional investors seeking stability and consistent returns.